Cardiol Therapeutics Enrolls 50% in Phase III Trial, ARCHER Shows 9.2g LV Mass Reduction
Cardiol Therapeutics has enrolled over half of patients in its pivotal Phase III MAVERIC trial for CardiolRx™ in recurrent pericarditis, targeting full enrollment by Q2 2026. The firm reported Phase II ARCHER data showing a 9.2g reduction in left ventricular mass, secured U.S. patent allowance through 2040, and raised $31 million to fund operations into Q4 2027.
1. Pivotal Phase III MAVERIC Trial
The MAVERIC trial is a randomized, double-blind, placebo-controlled study evaluating CardiolRx™ for the prevention of recurrent pericarditis. It plans to enroll approximately 110 patients across 25 clinical sites in the United States, has surpassed 50% enrollment, and expects full enrollment by Q2 2026 to support an NDA submission.
2. Positive Phase II ARCHER Results
ARCHER enrolled 109 patients across 34 sites in five countries and demonstrated a 9.2g reduction in left ventricular mass after 12 weeks of CardiolRx™ treatment. Multiple cardiac MRI endpoints improved, indicating structural recovery from inflammation-driven edema with a safety profile consistent with prior studies.
3. Patent Protection and CRD-38 Program Advancement
A U.S. patent allowance has been granted broadly covering CardiolRx™ and the next-generation CRD-38 compound through late 2040. The CRD-38 program is advancing toward an IND application and Phase I clinical development for heart failure and other inflammatory cardiac conditions.
4. Funding and Board Strengthening
Cardiol Therapeutics raised gross proceeds of $31 million, providing a cash runway into Q4 2027 to support ongoing trials and pipeline advancement. The board was strengthened with the election of Dr. Timothy Garnett, former Chief Medical Officer of Eli Lilly, enhancing clinical leadership.